PharmaShots | Incisive News in 3 Shots

Subscribe Now

Legend Biotech

$Janssen and Legend Biotech Report the sBLA Submission of Carvykti (ciltacabtagene autoleucel) to the US FDA for Relapsed or Refractory Multiple Myeloma$

Janssen and Legend Biotech Report the sBLA Submission of Carvykti (ciltacabtagene autoleucel) to the US FDA for Relapsed or Refrac...

June 7, 2023

Legend Biotech Reports NMPA’s Acceptance of NDA for Ciltacabtagene Autoleucel (Cilta-Cel) in Multiple Myeloma

Legend Biotech Reports NMPA’s Acceptance of NDA for Ciltacabtagene Autoleucel (Cilta-Cel) in Multiple Myeloma

January 2, 2023

Legend Biotech’s Carvykti (ciltacabtagene autoleucel) Receives the US FDA’s Approval for the Treatment of Multiple Myeloma

Legend Biotech’s Carvykti (ciltacabtagene autoleucel) Receives the US FDA’s Approval for the Treatment of Multiple Myeloma

March 1, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us